Teflaro Sanctioned for Bacterial Infections
Including pneumonia and methicillin-resistant staph
MONDAY, Nov. 1 (HealthDay News) -- The injected antibiotic Teflaro (ceftaroline fosamil) has been approved by the U.S. Food and Drug Administration to treat bacterial infections including community acquired bacterial pneumonia and methicillin-resistant Staphylococcus aureus (MRSA), the agency said in a news release.
Teflaro is among the cephalosporin class of antibiotics, which treat infections by interfering with the bacterial cell wall.
In clinical testing, the most common side effects of Teflaro included diarrhea, nausea and rash. The drug shouldn't be used by people with a known history of allergy or sensitivity to cephalosporins, the FDA said.
The FDA has more about this approval.